Inactive Instrument

Taiwan Liposome Company, Ltd.

Equities

4152

TW0004152004

Biotechnology & Medical Research

Taiwan Liposome Company, Ltd. Receives TFDA Acceptance of IND Application of TLC19 for COVID-19

October 06, 2020 at 10:24 am

Taiwan Food and Drug Administration (TFDA) has accepted Taiwan Liposome Company, Ltd.'s Investigational New Drug (IND) application for a Phase 1 clinical trial studying TLC19 Hydroxychloroquine Liposome Inhalation Suspension.

Latest news about Taiwan Liposome Company, Ltd.

Endo Ventures Limited Executes Agreement with Taiwan Liposome Company, Ltd. to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain	13/06/22	CI
TLC BioSciences Announces Publication of Tlc599 Phase Ii Results in Arthritis Research & Therapy	07/03/22	CI
Woods Investment Company, Ltd. completed the acquisition of Taiwan Liposome Company, Ltd. from a group of sellers.	07/10/21	CI
Taiwan Liposome Company, Ltd.(NasdaqGM:TLC) dropped from NASDAQ Composite Index	29/09/21	CI
Taiwan Liposome : to Voluntary Delist From Nasdaq	08/09/21	MT
TAIWAN LIPOSOME : HC Wainwright Lowers Taiwan Liposome to Neutral From Buy, Price Target to $7.50 From $11	13/07/21	MT
TAIWAN LIPOSOME : Laidlaw Downgrades Taiwan Liposome to Hold From Buy	07/07/21	MT
Woods Investment Company, Ltd. agreed to acquire Taiwan Liposome Company, Ltd. from a group of sellers for TWD 9.2 billion.	04/07/21	CI
Taiwan Liposome Company, Ltd. and Endo International plc Enter a Commercialization Agreement for A Liposomal Product	01/07/21	CI
TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India	27/05/21	CI
Taiwan Liposome : Working With Zydus Healthcare to Provide Supply of AmphoTLC in India	26/05/21	MT
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India	26/05/21	CI
Taiwan Liposome : TLC Secures India's Approval For Mucormycosis Treatment AmphoTLC	25/05/21	MT
Taiwan Liposome : Earnings Flash (TLC) TLC Posts Q1 Loss $-0.08	14/05/21	MT
Taiwan Liposome Company, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/05/21	CI
Taiwan Liposome Company, Ltd. announced a financing transaction	29/03/21	CI
Taiwan Liposome Company, Ltd. Provides Clinical Trail Update	05/02/21	CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	04/02/21	CI
Sector Update: Health Care Stocks Flat During Premarket Trading on Monday	28/12/20	MT
Taiwan Liposome : Completes Patient Enrollment in Study of TLC599 in Patients With Osteoarthritis Knee Pain	28/12/20	MT
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain	28/12/20	CI
Taiwan Liposome Company, Ltd. Announces Management Changes	22/12/20	CI
Taiwan Liposome : Reports 98% Enrollment of Phase 3 Study of Osteoarthritis Drug	18/12/20	MT
TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program	03/11/20	CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	27/10/20	CI

Chart Taiwan Liposome Company, Ltd.

Duration

Period

More charts

Company Profile

Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.43%	127B
REGENERON PHARMACEUTICALS, INC.	+24.58%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.84%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-14.89%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+12.47%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+56.65%	14.43B

Bio Therapeutic Drugs